VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical profit margin
Profit margin (net margin) is net income as a percentage of revenue.
VitaSpring Biomedical's profit margin for the twelve months ending Oct 31, 2022 was 11.7%. For fiscal 2022 it was 16.2%, against 171.4% the year before. The highest annual figure on record is 171.4% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Jan 31, 2022 | 16.2% | −155.2 |
| FY2021 | Jan 31, 2021 | 171.4% | +125.7 |
| FY2020 | Jan 31, 2020 | 45.7% | +176.1 |
| FY2019 | Jan 31, 2019 | -130.4% | −91.1 |
| FY2018 | Jan 31, 2018 | -39.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | 18.6% | −25.6 |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | 16.8% | −186.7 |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | 374.2% | −152.6 |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | -18.0% | +99.9 |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | 44.1% | +132.8 |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | 203.5% | +17606.1 |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | 526.9% | +1125.3 |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | -117.9% | −157.9 |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | -88.7% | +147.1 |
| Q3 FY2019CQ3 2018 | Oct 31, 2018 | -17402.7% | −17396.5 |
| Q2 FY2019CQ2 2018 | Jul 31, 2018 | -598.4% | −575.1 |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | 40.0% | +58.0 |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | -235.8% | – |
| Q3 FY2018CQ3 2017 | Oct 31, 2017 | -6.2% | – |
| Q2 FY2018CQ2 2017 | Jul 31, 2017 | -23.4% | – |
| Q1 FY2018CQ1 2017 | Apr 30, 2017 | -18.0% | – |
See a number that looks wrong?